COVID vaccines are set to be among the most lucrative pharmaceutical products ever

www.npr.org
4 min read
fairly easy
How much money have Pfizer and Moderna made off their COVID-19 vaccines? They're shaping up to be the most lucrative pharmaceutical products ever.
COVID vaccines are set to be among the most lucrative pharmaceutical products ever



ARI SHAPIRO, HOST:

The COVID-19 vaccines are making the pharmaceutical industry a lot of money. And while there are still millions more people to vaccinate and boost around the world, it's not clear exactly how long the boom will last. NPR pharmaceuticals correspondent Sydney Lupkin reports.

SYDNEY LUPKIN, BYLINE: This year, Pfizer expects to bring in $36 billion from worldwide sales of its COVID-19 vaccine. That would shatter the previous record in annual sales for a single pharmaceutical product - about $20 billion for the anti-inflammatory drug Humira - and make the Pfizer vaccine the bestselling pharmaceutical product ever. Moderna will deliver fewer doses but is still expecting up to $18 billion in sales for the year for its COVID-19 vaccine. But the long-term measure of financial success for the companies' mRNA vaccines isn't so simple. Here's Richard Evans of SSR Health, an investment research firm.

RICHARD EVANS: The benchmark,…
Sydney Lupkin
Read full article